Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:47 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 241–264 of 1,742 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Formulation #2 Clear all
Completed Phase 3 Interventional Results available

Recent-Onset Type 1 Diabetes Trial Evaluating Efficacy and Safety of Teplizumab

NCT03875729
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
teplizumab, Placebo
Biological
Lead sponsor
Provention Bio, Inc.
Industry
Eligibility
8 Years to 17 Years
Enrollment
328 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
34
States / cities
San Diego, California • San Francisco, California • Walnut Creek, California + 30 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2024 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate Equivalence of Estradiol Vaginal Cream 0.01% to Estrace® Cream 0.01% in Atrophic Vaginitis

NCT03294538
View directory record Official record
Conditions
Atrophic Vaginitis
Interventions
Generic Estradiol Vaginal Cream USP, 0.01%, Estrace® Vaginal Cream USP, 0.01%, Vehicle Vaginal Cream
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
30 Years to 75 Years · Female only
Enrollment
663 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
44
States / cities
Tucson, Arizona • La Mesa, California • Sacramento, California + 33 more
Source: ClinicalTrials.gov public record
Updated Dec 26, 2019 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

A Study on the Immune Response and Safety of an Adjuvanted Human Papillomavirus Vaccine When Given to Healthy Women 16 to 26 Years of Age

NCT05496231
View directory record Official record
Conditions
Cervical Intraepithelial Neoplasia
Interventions
HPV9 High formulation, HPV9 Medium formulation, HPV9 Low formulation, Gardasil 9
Biological
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
16 Years to 26 Years · Female only
Enrollment
1,080 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
39
States / cities
San Diego, California • Wheat Ridge, Colorado • Coral Gables, Florida + 33 more
Source: ClinicalTrials.gov public record
Updated Feb 3, 2025 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of V118 Formulation C (V118C) in Healthy Participants (V118C-001)

NCT06611033
View directory record Official record
Conditions
Healthy
Interventions
V118C, V118, PREVNAR 20™, Saline
Biological
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years to 49 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
3
States / cities
Hallandale, Florida • Hollywood, Florida • Galveston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Compare the Pharmacokinetics and Safety of Mitapivat 100 mg Tablet Formulation With Mitapivat 2 × 50 mg Tablet Formulation in Healthy Adult Participants

NCT04696393
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Mitapivat tablet
Drug
Lead sponsor
Agios Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 64 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 13, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I 2-Way Crossover Study to Assess Relative BA of Tablet Versus Liquid Suspension and Food Effect on Tablet Formulation

NCT00867685
View directory record Official record
Conditions
Healthy
Interventions
AZD2624
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 65 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 30, 2009 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Food Effect and the Relative Bioavailability of the Cabotegravir (CAB) Pediatric Dispersible Tablet (DT) Formulation

NCT05776108
View directory record Official record
Conditions
HIV Infections
Interventions
Cabotegravir IR Formulation (reference), Cabotegravir DT Formulation (test 1), Cabotegravir DT Formulation (test 2)
Drug
Lead sponsor
ViiV Healthcare
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Dec 13, 2023 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2Phase 3 Interventional

Evaluating the Effects of Tasimelteon vs Placebo on Sleep Disturbances in SMS

NCT02231008
View directory record Official record
Conditions
Smith-Magenis Syndrome, Circadian
Interventions
tasimelteon, placebo
Drug
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
3 Years to 65 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
4
States / cities
Santa Monica, California • Baltimore, Maryland • Chevy Chase, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 18, 2022 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Mechanistic Characterization of Uterine Pain

NCT04145518
View directory record Official record
Conditions
Dysmenorrhea (Disorder), Dysmenorrhea Primary, Dysmenorrhea Secondary, Endometrial Diseases, Leiomyoma, Fibroid Uterus
Interventions
Naproxen Sodium, Placebo
Drug
Lead sponsor
Endeavor Health
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
183 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Evanston, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 23, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional

Dose Ranging Study of an Ocular Sirolimus (Rapamycin) Formulation in Patients With Diabetic Macular Edema

NCT00656643
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
Sirolimus, Placebo
Drug
Lead sponsor
Santen Inc.
Industry
Eligibility
18 Years and older
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Investigating the Pharmacokinetic Profiles of Four Extended Release Paracetamol Formulations

NCT01568749
View directory record Official record
Conditions
Analgesia
Interventions
Paracetamol, Paracetamol formulation 1, Paracetamol Formulation 2, Paracetamol formulation 3, Paracetamol formulation 4
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years to 50 Years
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Nov 24, 2014 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation Before Surgery in Treating Patients With Pancreatic Cancer That Can Be Removed by Surgery

NCT02562716
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Resectable Pancreatic Carcinoma
Interventions
Fluorouracil, Gemcitabine Hydrochloride, Irinotecan Hydrochloride, Oxaliplatin, Paclitaxel Albumin-Stabilized Nanoparticle Formulation, Pancreatectomy
Drug · Procedure
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years to 75 Years
Enrollment
147 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
807
States / cities
Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 515 more
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional

A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

NCT01682902
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1
Interventions
Faster-acting insulin aspart, insulin aspart
Drug
Lead sponsor
Novo Nordisk A/S
Industry
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 9, 2017 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Norwalk Vaccine Study

NCT00806962
View directory record Official record
Conditions
Norovirus
Interventions
Adjuvant/Excipients, placebo, Norwalk VLP Vaccine
Drug · Device · Biological
Lead sponsor
LigoCyte Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
61 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Baltimore, Maryland • St Louis, Missouri • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated May 6, 2015 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay

NCT02822261
View directory record Official record
Conditions
Sunscreening Agent
Interventions
Coppertone (BAY987516)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 12, 2018 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Results available

Multicenter Study Of CPX-1 (Irinotecan HCl: Floxuridine) Liposome Injection In Patients With Advanced Colorectal Cancer

NCT00361842
View directory record Official record
Conditions
Colorectal Neoplasms
Interventions
CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Drug
Lead sponsor
Jazz Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
65 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
11
States / cities
Greenbrae, California • Washington D.C., District of Columbia • Coral Springs, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Terminated Phase 1 Interventional Results available

BVD-523 Plus Nab-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Cancer

NCT02608229
View directory record Official record
Conditions
Pancreatic Cancer, Cancer of Pancreas, Cancer of the Pancreas, Pancreas Cancer
Interventions
BVD-523, Nab-paclitaxel, Gemcitabine, Tumor biopsy
Drug · Procedure
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 21, 2021 · Synced Oct 31, 2026, 1:47 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Dose Regimen Study of SLI-F06 in Healthy Volunteers

NCT05501327
View directory record Official record
Conditions
Scar, Wound Healing
Interventions
SLI-F06
Drug
Lead sponsor
Scarless Laboratories, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
2
States / cities
Encinitas, California • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jul 27, 2023 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Study Comparing the Efficacy of Two Ibuprofen Formulations

NCT00740857
View directory record Official record
Conditions
Pain
Interventions
placebo, ibuprofen Formulation 1, ibuprofen Formulation 2
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
16 Years to 40 Years
Enrollment
211 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Sun Protection Factor Assay (SPF Assay 201/2016)

NCT02930772
View directory record Official record
Conditions
Sunscreening Agents
Interventions
BAY987516
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 70 Years
Enrollment
11 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Union, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 13, 2018 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 3 Interventional Results available

Study to Compare U0267 Against Vehicle in Subjects With Plaque-type Psoriasis Two of Two Phase 3 Studies

NCT00689481
View directory record Official record
Conditions
Psoriasis
Interventions
U0267 Foam, Vehicle foam
Drug
Lead sponsor
Stiefel, a GSK Company
Industry
Eligibility
12 Years and older
Enrollment
323 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
12
States / cities
Mobile, Alabama • Fremont, California • Ormond Beach, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Oct 7, 2016 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants

NCT05112939
View directory record Official record
Conditions
Healthy
Interventions
RPV LA, CAB LA
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
126 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2024
U.S. locations
2
States / cities
Lenexa, Kansas • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced Oct 31, 2026, 1:47 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluating Safety and Effectiveness of Octenidine Dihydrochloride

NCT03140254
View directory record Official record
Conditions
Preoperative Skin Preparation
Interventions
Chlorhexidine gluconate, N,N'-(1,10-decanediyldi-1(4H)-Pyridinyl-4-ylidene)-Bis-(1-octanamine) Dihydrochloride, Placebo
Drug
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older
Enrollment
145 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Butte, Montana
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 31, 2026, 1:47 AM EDT
Recruiting Phase 2 Interventional

Testing the Addition of an Individualized Vaccine to Durvalumab and Tremelimumab and Chemotherapy in Patients With Metastatic Triple Negative Breast Cancer

NCT03606967
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 31, 2026, 1:47 AM EDT